LONGECITY

http://www.reuters.c...lBrandChannel=0

http://www.reuters.c...lBrandChannel=0

Proving bioavailability and impact in humans beyond a doubt. Guessing from reading a couple of threads, it seems like the community has a good handle on what they are doing with resv to make sirt501

Very surprising that at 2.5 and 5 grams per day they did not find a significant reduction in blood glucose. At approximately 33 subjects per group with Type II diabetes, this study would have been adequately powered to detect a difference with current therapeutic standards. However, the Sirtris spin machine makes it sound like this study is all good news, which misleads investors. On top of that, you have Sinclair giving media bites about the study when he is on the SAB and will directly benefit from a positive interpretation of the data. This is quite dubious because he is unqualified to interpret this data...after all he is a yeast guy not a pharmacologist or anything remotely close to a clinical scientist. For us, it is reassuring that high dose resveratrol appeared safe over 28-days in a higher risk group.
Edited by billypc99, 08 January 2008 - 06:14 PM.

Right, who knows/cares how much positive spin they put on this. For us, the safety data at 2.5 and 5 grams/d doseage is the more relevant info, IMHO....

Very surprising that at 2.5 and 5 grams per day they did not find a significant reduction in blood glucose. At approximately 33 subjects per group with Type II diabetes, this study would have been adequately powered to detect a difference with current therapeutic standards. However, the Sirtris spin machine makes it sound like this study is all good news, which misleads investors. On top of that, you have Sinclair giving media bites about the study when he is on the SAB and will directly benefit from a positive interpretation of the data. This is quite dubious because he is unqualified to interpret this data...after all he is a yeast guy not a pharmacologist or anything remotely close to a clinical scientist. For us, it is reassuring that high dose resveratrol appeared safe over 28-days in a higher risk group.

They do appear to have found an increase in insulin sensitivity. Standard glucose challenge, two hours post sugar intake, the diabetics' blood glucose was 28% lower than controls.

Seems as though the release helped SIRT open up a couple of points higher, and the volume was about 50% higher for the day over the average.

I don't this says much for SIRT, maybe more for us, as I don't give a rats ass what it does to my glucose. I'd really like to see the rest of the "fat mice" data.

The rest of the data were presented at the American Aging Association Annual Meeting in Texas last June....1.5 years after the initial data were reported. This was only an abstract presentation. Some have speculated the publication of the data have been delayed so it wouldn't interfere with Sitris' investor relations. It was suggested that they new by submitting the data as an abstract to a conference they could at least delay the publication of the data until the end of the conference when the copyright embargo is lifted. Imagine if the data were included in the initial Nature paper or just before the IPO? That would have been a major loss of cashola.

The rest of the data were presented at the American Aging Association Annual Meeting in Texas last June....1.5 years after the initial data were reported. This was only an abstract presentation. Some have speculated the publication of the data have been delayed so it wouldn't interfere with Sitris' investor relations. It was suggested that they new by submitting the data as an abstract to a conference they could at least delay the publication of the data until the end of the conference when the copyright embargo is lifted. Imagine if the data were included in the initial Nature paper or just before the IPO? That would have been a major loss of cashola.

What exactly was the data? Something that looks bad for Sirtris' "story"?

The rest of the data were presented at the American Aging Association Annual Meeting in Texas last June....1.5 years after the initial data were reported. This was only an abstract presentation. Some have speculated the publication of the data have been delayed so it wouldn't interfere with Sitris' investor relations. It was suggested that they new by submitting the data as an abstract to a conference they could at least delay the publication of the data until the end of the conference when the copyright embargo is lifted. Imagine if the data were included in the initial Nature paper or just before the IPO? That would have been a major loss of cashola.

The Nature report came out in November of 2006. Where does the "1.5 years" come from? Looking at the schedule of the meeting I can find no presentation by Sirtris. Do you have any info on what the results were or do I just have to take your word for it? Many people have been wondering where that data is so we'd love to here some details.

The paper was presented by one of the co-authors of the Nature paper; from the conference:

Lifespan Extension by Resveratrol
Rafael de Cabo, PhD, National Institute on Aging, MD

If anyone has access to it....